Understanding GLP-1 Medications
Known by brand names like Ozempic, Wegovy, Mounjaro, and Zepbound, GLP-1 receptor agonists have transformed the treatment of type 2 diabetes and obesity. These drugs work by mimicking a gut hormone that helps regulate blood sugar, reduces appetite, and slows
stomach emptying, leading to significant weight loss for many users. Beyond weight control, major clinical trials have also proven these medications provide substantial protection for the heart, reducing the risk of cardiovascular problems. This has made them a cornerstone of modern metabolic medicine, with an estimated one in eight U.S. adults now using them.
The Alarming Findings on Discontinuation
Recent research has shifted focus from the benefits of starting these drugs to the potential risks of stopping them. Two notable studies have highlighted this concern. An Italian study published in 'The Lancet Regional Health – Europe' analysed data from over 80,000 patients with type 2 diabetes. It found that those who discontinued their GLP-1 medication had approximately double the risk of a non-fatal heart attack, non-fatal stroke, or death from any cause compared to those who continued the treatment. The group that stopped taking the drugs saw 3.94 of these major events per 100 person-years, versus just 1.96 for those who remained on the medication.
The 'Metabolic Whiplash' Effect
Another large study from Washington University School of Medicine in St. Louis, which followed over 333,000 U.S. veterans with type 2 diabetes, echoed these findings. Researchers found that stopping GLP-1 treatment for as little as six months was linked to a significant increase in the risk of major cardiovascular events. The risk grew the longer a person was off the medication, increasing by up to 22% after two years of discontinuation. Dr. Ziyad Al-Aly, the study's senior author, described the effect as a 'metabolic whiplash'. When treatment stops, it's not just the weight that returns; there is also a resurgence in inflammation, blood pressure, and cholesterol, which can be detrimental to heart health.
Why Does Risk Increase After Stopping?
Experts believe the increased risk is not necessarily because stopping the drug causes a heart attack, but rather because continuous use is what prevents it. The protective benefits appear to be temporary and contingent on staying on the medication. When a person stops treatment, they lose those benefits. This is often accompanied by weight regain, which itself is linked to higher blood pressure and cholesterol. A study published in the 'BMJ' found that people tend to regain weight rapidly after stopping these drugs, with cardiometabolic markers like blood pressure and cholesterol returning to pre-treatment levels within about a year and a half.
What The Experts Advise
Researchers and doctors are clear: these findings should not cause panic but should reinforce the understanding that obesity and type 2 diabetes are chronic conditions that require long-term management. High discontinuation rates—with some studies showing up to 60% of patients stopping within a year due to side effects, cost, or inconvenience—are a major concern. The authors of the Italian study noted that their findings are observational and don't prove causation; it's possible that patients who stopped were already in poorer health. However, the consensus is strong on one point: patients should not stop taking their GLP-1 medication without first consulting their healthcare provider. The decision to discontinue should be a carefully considered medical one, not a casual choice made after reaching a weight-loss goal.
















